{"id":"W1808718376","doi":"10.6004/jnccn.2013.0217","title":"Emerging Treatments in Recurrent and Metastatic Colorectal Cancer","year":2013,"lang":"en","type":"review","venue":"Journal of the National Comprehensive Cancer Network","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Sanofi; Bayer HealthCare; Regeneron Pharmaceuticals; Amgen; Pfizer; Oncolytics Biotech; Eli Lilly and Company; Bristol-Myers Squibb; Genentech; Bayer","keywords":"Medicine; Bevacizumab; Cetuximab; Regorafenib; Panitumumab; Colorectal cancer; Aflibercept; Oncology; Chemotherapy; Targeted therapy; Epidermal growth factor receptor; Internal medicine; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006492813,0.0007219883,0.001465059,0.002890098,0.0002867209,0.0007992919,0.000872644,0.000882104,0.003502242],"category_scores_gemma":[0.0008640288,0.0002461965,0.0006272478,0.002501336,0.0003905821,0.001085971,0.0006649133,0.00159658,0.001364802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006698964,"about_ca_system_score_gemma":0.001034981,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001454884,"about_ca_topic_score_gemma":0.003472604,"domain_scores_codex":[0.9997672,0.00005366403,0.00004157752,0.00003001748,0.00008873949,0.00001874015],"domain_scores_gemma":[0.999667,0.0001592038,0.000054866,0.000008790154,0.00008775525,0.00002244552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006679343,0.00006302987,0.0001628975,0.02556713,0.0001092243,0.0001847119,0.00005506914,0.000222614,0.0006419324,0.002227948,0.02040689,0.9502918],"study_design_scores_gemma":[0.0000427608,0.0001162022,0.001110949,0.01136586,0.0002182348,0.001679622,0.00009510986,0.00009241127,0.0002984529,0.001785375,0.9831784,0.00001668223],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006661189,0.9991615,0.00003582954,0.0001279277,0.00008908175,0.000003967801,0.000008376181,0.000002514588,0.0005042831],"genre_scores_gemma":[0.0004233045,0.999027,0.00009603837,0.000130206,0.000076681,0.000004864734,0.00001712119,6.003357e-7,0.0002242513],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003502242,"threshold_uncertainty_score":0.01171619,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1069024573120856,"score_gpt":0.4167122480531281,"score_spread":0.3098097907410425,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}